EGFR and leukemia: In addition, among the NCI60 cell lines, mutations in the EGFR gene have been identified in the leukemia cell line (RPMI-8226) and melanoma cell line (SK-MEL-28) and were found to be associated with the resistant of these cell lines to 12 tyrosine kinase inhibitors (TKI) including the erlotinib (67, 68). It is, therefore, noteworthy that NSC765598 demonstrated high activity on these cells line (Figure 11, Table 5).